5VT0.F vTv Therapeutics Inc.

Healthcare Biotechnology Frankfurt Exchange
18.50 EUR
Close of Nov 11, 2026
18.50 37.20
Market cap
EUR 74.2M
P/E
-
P/B
1.17x
ROE
-1.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 5VT0.F undervalued?

Graham number

The Graham number of vTv Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

vTv Therapeutics Inc. fundamental analysis

No fundamental analysis for vTv Therapeutics Inc. yet.

vTv Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About vTv Therapeutics Inc.

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic d…

Full company profile